Vibegron 2026 Research Updates: New Evidence for Overactive Bladder Treatment

　　In 2026,clinical research on vibegron has primarily focused on three major directions:confirmation of efficacy in overactive bladder(OAB),evaluation of long-term medication safety,and therapeutic expansion in male patient populations with concomitant benign prostatic hyperplasia(BPH).From the perspective of the overall research system,the clinical evidence for this drug has gradually evolved from early short-term randomized controlled trials to long-term real-world sample analyses,forming a relatively complete evidence-based medicine chain.

　　The core basis for vibegron's approval by the U.S.FDA came from the EMPOWUR phase III clinical trial.This was a 12-week,double-blind,randomized,placebo-controlled study that also included tolterodine as an active comparator,enrolling a total of 1515 patients meeting the diagnostic criteria for overactive bladder.Patients were randomly assigned in a 5:5:4 ratio to receive vibegron 75mg,placebo,or tolterodine treatment.All enrolled patients presented with typical OAB symptoms,including increased daily urinary frequency,urgency episodes,and urinary incontinence.

　　The co-primary endpoints of the study were the change from baseline in daily micturition frequency at week 12 and the change in urge urinary incontinence(UUI)episode frequency.The results showed that the vibegron group had an average reduction of approximately 1.8 daily micturitions from baseline,which was superior to the 1.3 reduction in the placebo group and also better than the 1.6 reduction in the active comparator tolterodine group.In terms of urinary incontinence control,the vibegron group achieved an average reduction of about 2 urge urinary incontinence episodes per day,also significantly superior to both control groups.Regarding secondary endpoints,including urgency episode frequency,increase in voided volume per micturition,and proportion of patients with improved urinary incontinence symptoms,vibegron demonstrated consistent advantages,confirming its comprehensive benefits in symptom control and patient quality of life improvement.

　　In terms of safety,the most common adverse events in the EMPOWUR study were mainly diarrhea,nausea,headache,upper respiratory tract infection,and nasopharyngitis,most of which were mild to moderate reactions.The overall tolerability was good,and no significant systemic serious adverse events were observed.

　　In the field of long-term research,the EMPOWUR extension study further evaluated the sustained efficacy and safety of vibegron for more than 40 weeks,enrolling approximately 500 patients who completed the initial trial.The results showed that after 52 weeks of continuous treatment,the proportion of patients with wet OAB who achieved more than a 75%reduction in urinary incontinence episodes increased significantly,and symptom improvement remained stable during long-term follow-up,demonstrating more durable efficacy maintenance compared to tolterodine.This finding suggests that vibegron is not only suitable for short-term symptom control but also has good long-term disease management value.

　　For the male overactive bladder population,the URO-901-3005 phase III study further expanded its indications.This trial enrolled 1105 male OAB patients who were already receiving medication for benign prostatic hyperplasia.The results showed that at week 12 of treatment,the vibegron group had significantly greater reductions in daily micturition frequency and urgency episodes compared to the placebo group.Additionally,improvements in nocturia frequency,increase in voided volume per micturition,and improvement in prostate symptom scores all reached statistical significance,indicating its important value in the management of complex urinary symptoms in men.

　　The subsequent URO-901-3006"COURAGE trial"further verified the long-term efficacy,with follow-up continuing from 24 weeks to 52 weeks.The results showed that patients who continued to use vibegron maintained stable efficacy,while patients who switched from placebo to treatment also gradually achieved symptom improvement,suggesting that its therapeutic effect has a certain cumulative effect.In terms of safety,the more common adverse events included hypertension,COVID-19 infection,and mild liver enzyme elevation,but the overall incidence was low and did not affect the feasibility of long-term use of the drug.